Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Ascendis Pharma AS

Healthcare US ASND

216.79USD
0.19(0.09%)

Last update at 2026-06-03T20:00:00Z

Day Range

214.17218.24
LowHigh

52 Week Range

150.89250.74
LowHigh

Fundamentals

  • Previous Close 216.60
  • Market Cap15064.65M
  • Volume379563
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-131.41500M
  • Revenue TTM720.13M
  • Revenue Per Share TTM11.88
  • Gross Profit TTM 625.22M
  • Diluted EPS TTM-4.45

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -204.25826M -373.24100M -474.14400M -577.81700M -383.94400M
Minority interest - - - - -
Net income -219.03414M -378.08400M -481.44700M -583.19400M -383.57700M
Selling general administrative 448.04M 284.55M 264.41M 221.23M 160.18M
Selling and marketing expenses - - - - -
Gross profit 588.53M 319.38M 222.32M 39.04M 4.25M
Reconciled depreciation 17.70M 17.71M 18.91M 17.96M 15.39M
Ebit -130.89277M -307.73700M -430.07900M -573.67457M -439.67296M
Ebitda -113.89518M -290.02300M -411.16800M -556.04000M -423.66800M
Depreciation and amortization 17.00M 17.71M 18.91M 17.63M 16.00M
Non operating income net other - - - - -
Operating income -130.89277M -278.76300M -455.54100M -561.81400M -451.79200M
Other operating expenses 822.60M 642.40M 722.26M 612.99M 459.57M
Interest expense 77.46M 65.50M 44.06M 50.49M 3.91M
Tax provision 15.38M 4.84M 7.30M 5.38M -0.36700M
Interest income 15.30M 14.36M 16.86M 7.43M 0.69M
Net interest income -44.87700M -51.14300M -27.20800M -43.06100M -3.21900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 14.78M 4.84M 7.30M 5.38M -0.36700M
Total revenue 691.71M 363.64M 266.72M 51.17M 7.78M
Total operating expenses 719.42M 598.15M 677.86M 600.85M 456.05M
Cost of revenue 103.18M 44.26M 44.40M 12.14M 3.52M
Total other income expense net -73.36550M -94.47800M -18.60300M -16.00300M 67.85M
Discontinued operations - - - - -
Net income from continuing ops -228.03400M -378.08400M -481.44700M -583.19400M -383.57700M
Net income applicable to common shares - - - -583.19400M -383.57700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1302.02M 1179.49M 825.59M 1089.74M 1084.92M
Intangible assets 0.21M 0.53M 0.92M 1.33M 1.78M
Earning assets - - - - -
Other current assets 33.70M 39.43M 38.58M 31.72M 25.23M
Total liab 1464.77M 1285.20M 971.28M 826.39M 201.29M
Total stockholder equity -162.75165M -105.70600M -145.69700M 263.35M 883.63M
Deferred long term liab - - - - -
Other current liab 487.05M 317.77M 76.19M 44.82M 31.34M
Common stock 8.32M 8.15M 7.75M 7.67M 7.65M
Capital stock 8.32M 8.15M 7.75M 7.67M 7.65M
Retained earnings -2699.23784M -2559.70000M -2278.97325M -1860.49300M -1413.85500M
Other liab - - - 172.16M 2.96M
Good will 3.49M 3.50M 3.50M 3.50M 3.50M
Other assets - - - 1.92M 1.81M
Cash 615.78M 559.54M 392.16M 444.77M 446.27M
Cash and equivalents - - - - -
Total current liabilities 1068.94M 907.86M 197.34M 171.27M 100.36M
Current deferred revenue 4.94M 0.94M 1.18M - 2.60M
Net debt 255.64M 297.07M 252.10M 63.61M -341.30600M
Short term debt 486.32M 491.54M 25.40M 25.42M 7.00M
Short long term debt 486.53M 491.54M 11.23M 25.42M -
Short long term debt total 871.41M 856.62M 644.26M 508.38M 104.96M
Other stockholder equity 2529.92M 2444.06M 2132.43M 3.45M 203.71M
Property plant equipment - - - 129.09M 126.05M
Total current assets 1108.51M 1060.86M 702.72M 923.47M 805.89M
Long term investments 32.53M 13.57M 5.69M 30.42M 145.91M
Net tangible assets - - - 258.52M 878.36M
Short term investments - 0.00000M 7.28M 290.69M 235.80M
Net receivables 157.63M 166.28M 55.77M 25.63M 23.19M
Long term debt 385.25M 365.08M 534.25M 482.96M -
Inventory 301.40M 295.61M 208.93M 130.67M 75.41M
Accounts payable 90.62M 96.39M 94.57M 101.03M 59.42M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.75425M 1.78M -153.44600M 255.67M 875.99M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 2.32M 2.13M 1.92M 1.81M
Deferred long term asset charges - - - - -
Non current assets total 193.50M 118.63M 122.87M 166.27M 279.04M
Capital lease obligations - - 98.79M - 104.96M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M 6.88M 279.03M 61.73M -86.34500M
Change to liabilities - - - 54.59M 44.39M
Total cashflows from investing activities -8.15012M 6.88M - 61.73M -110.57900M
Net borrowings -21.95800M 122.79M - 496.93M -6.42900M
Total cash from financing activities 34.89M 443.93M 134.29M 396.77M 351.39M
Change to operating activities - - - -6.40900M -11.23800M
Net income -219.03414M -378.08400M -481.44700M -583.19400M -383.57700M
Change in cash 122.65M 167.38M -52.60300M -1.50000M -138.25000M
Begin period cash flow 493.13M 392.16M 444.77M 446.27M 584.52M
End period cash flow 615.78M 559.54M 392.16M 444.77M 446.27M
Total cash from operating activities 51.77M -306.19700M -467.36100M -495.69900M -417.64900M
Issuance of capital stock 0.00000M 309.91M 0.00000M 0.19M 367.88M
Depreciation 17.00M 17.71M 18.91M 17.96M 15.39M
Other cashflows from investing activities - 0.95M - 9.54M 9.54M
Dividends paid - - - 5.06M 33.14M
Change to inventory -5.68635M -86.67800M -78.25800M -55.26800M -75.40500M
Change to account receivables 14.97M -118.60700M -32.10121M -11.32333M -6.65900M
Sale purchase of stock -16.70943M 0.00000M -1.81200M -105.30500M -21.60500M
Other cashflows from financing activities -10.94623M 11.22M 8.47M 5.15M 44.68M
Change to netincome - - - 88.15M -0.54900M
Capital expenditures 8.15M 1.43M 2.44M 14.49M 24.23M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 68.16M -107.15700M -99.78600M -18.61700M -48.91400M
Stock based compensation 116.17M 95.51M 66.66M 64.18M 66.83M
Other non cash items 182.44M 60.98M 21.00M 18.60M -67.01200M
Free cash flow 43.62M -307.62400M -469.80300M -510.18800M -441.88300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ASND
Ascendis Pharma AS		 0.19 0.09% 216.79 - 47.17 20.92 78.13 18.05 -20.7458
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Ascendis Pharma AS

Tuborg Boulevard 12, Hellerup, Denmark, 2900

Key Executives

Name Title Year Born
Mr. Jan Moller Mikkelsen Pres, CEO, Member of Exec. Board & Exec. Director 1960
Mr. Michael Wolff Jensen L.L.M. Sr. VP, Chief Legal Officer & Member of the Exec. Board 1971
Dr. Birgitte Volck M.D., Ph.D. Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs 1962
Mr. Scott T. Smith CFO, Sr. VP & Member of Exec. Board 1974
Ms. Lotte Sonderbjerg Chief Admin. Officer, Sr. VP & Member of the Exec. Board 1961
Mr. Peter Rasmussen VP of Fin. & Principal Accounting Officer 1969
Mr. Timothy J. Lee Sr. Director of Investor Relations NA
Mr. Flemming Steen Jensen Sr. VP of Product Supply & Quality 1961
Dr. Kennett Sprogoe Sr. VP and Head of Innovation & Research 1979
Dr. Jens Sigurd Okkels Ph.D. Sr. VP of Product Devel. 1961

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions